Jun 8, 2026 12:00PM
Apr 2, 2026 12:30PM
Jan 7, 2026 12:00PM
Jan 6, 2026 12:12PM
Jan 6, 2026 12:12PM
Nov 27, 2025 12:00PM
Nov 27, 2025 12:00PM GENFIT Announces Appointment of new Chief Medical Officer
Sep 22, 2025 04:10PM
May 14, 2025 04:10PM
Apr 29, 2025 03:10PM
Mar 20, 2025 05:10PM
Sep 13, 2023 01:30AM
Apr 13, 2023 04:10PM
Nov 17, 2022 04:10PM GENFIT Pipeline Day Highlights Diverse Product Portfolio in Underserved Liver Diseases
Sep 28, 2022 04:10PM
Sep 19, 2022 05:59AM
Sep 19, 2022 01:30AM
Sep 13, 2022 04:10PM
Sep 13, 2022 04:10PM
Dec 17, 2021 05:58AM
Dec 17, 2021 01:00AM Ipsen and GENFIT Enter Into Exclusive Licensing Agreement for Elafibranor, a Phase III Asset Evaluated in Primary Biliary Cholangitis, as Part of a Long-Term Global Partnership
Dec 17, 2021 01:00AM
Nov 2, 2021 05:10PM
Sep 29, 2021 04:10PM
Feb 9, 2021 04:22PM
Feb 9, 2021 04:10PM
Sep 30, 2020 04:05PM
Sep 28, 2020 09:30AM Pre-Open Stock Movers 09/28: (PLL) (PRCP) (GNFT) Higher; (INO) (AQST) (VIPS) Lower (more...)
Sep 24, 2020 04:14PM
Sep 24, 2020 04:10PM
Jul 22, 2020 04:05PM
May 18, 2020 04:15PM
May 12, 2020 07:38AM
Apr 8, 2020 04:40PM
Mar 31, 2020 02:45AM GENFIT: Update on Regulatory and Clinical Activities Amid the COVID-19 Pandemic
Feb 21, 2020 09:12AM
Feb 20, 2020 05:52PM
Feb 20, 2020 05:42PM
Feb 20, 2020 04:08PM
Feb 20, 2020 04:05PM
Nov 26, 2019 05:51AM
Nov 26, 2019 02:46AM GENFIT: Positive 42-month DSMB Recommendation for Continuation of Phase 3 RESOLVE-IT Study of Elafibranor in NASH
Nov 10, 2019 08:00AM
Oct 31, 2019 02:45AM
Sep 30, 2019 04:45PM
Sep 26, 2019 04:15PM
Sep 9, 2019 02:03AM
Sep 2, 2019 12:21PM
Jul 29, 2019 02:19AM GENFIT: FDA and EMA Grant GENFIT’s Elafibranor Orphan Drug Designation for Primary Biliary Cholangitis (PBC)
Jun 24, 2019 04:12PM

322,995 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All